Symbiotec Pharmalab IPO Details Details

Symbiotec Pharmalab is coming up with a ₹1,757 crore book-built IPO, comprising a fresh issue of ₹150 crore (approximately 0.15 crore shares) and a significantly larger Offer for Sale (OFS) of ₹1,607 crore (approximately 1.63 crore shares). The IPO will open for subscription on August 24, 2026, and close on August 27, 2026. The allotment is expected to be finalized on August 28, while the shares are tentatively scheduled to list on NSE and BSE on September 1, 2026. The company has fixed the price band at ₹938–₹988 per share, with a lot size of 15 shares. At the upper end of the price band, the minimum investment required for a retail investor is ₹14,820 for one lot. JM Financial Ltd. is the book-running lead manager for the IPO, while MUFG Intime India Pvt. Ltd. is acting as the registrar to the issue. IPO Snapshot Issue Size: ₹1,757 Cr Fresh Issue: ₹150 Cr Offer for Sale (OFS): ₹1,607 Cr Price Band: ₹938–₹988/share Lot Size: 15 shares Minimum Retail Investment: ₹14,820 IPO Opens: August 24, 2026 IPO Closes: August 27, 2026 Allotment: August 28, 2026 Tentative Listing: September 1, 2026 Exchange: NSE & BSE A key point for investors is that ₹1,607 crore out of the total ₹1,757 crore issue is an OFS, meaning the majority of the IPO proceeds will go to the selling shareholders rather than the company. Only the ₹150 crore fresh issue will bring new capital into Symbiotec Pharmalab. Investors should refer to the company's Red Herring Prospectus (RHP) for complete information on its business, financial performance, use of fresh issue proceeds, valuations and key risk factors.

IPO Details

IPO Date 24 Aug 26
Listing Date 01 Sep 26
Face Value ₹2 per share
Price Band ₹938 to ₹988
Lot Size 15
Sale Type Fresh capital cum OFS
Issue Type Bookbuilding IPO
Listing At NSE, BSE
Total Issue Size ₹1,757 Cr
Fresh Issue
₹150 Cr
Offer for Sale
Share Holding Pre Issue 6,16,81,496 shares
Share Holding Post Issue 6,32,02,757 shares

IPO DRHP Status

Description Details

IPO Reservation

Investor Category Shares Offered
QIB Shares Offered Not more than 50% of the Net Offer
Retail Shares Offered Not less than 35% of the Net Offer
NII Shares Offered Not less than 15% of the Net Offer

About Symbiotec Pharmalab IPO Details.


Incorporated in 2002, Symbiotec Pharmalab Limited is a pharmaceutical and biotechnology company engaged in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), nutritional ingredients and specialty products. The company caters to both domestic and international customers across regulated as well as emerging pharmaceutical markets. Symbiotec traces its operating journey to 1995, when it began as a lab-scale manufacturer of steroidal hormone APIs. Over the years, it has evolved into an industrial-scale, backward-integrated manufacturing platform, building more than three decades of experience in pharmaceutical manufacturing and related technologies. Regulatory Approvals & Global Standards The company has established a strong regulatory track record, with its operations and manufacturing capabilities receiving approvals or certifications from major global regulatory authorities, including: United States Food and Drug Administration (US FDA) European Union Good Manufacturing Practices (EU-GMP) Ministry of Food and Drug Safety (MFDS), South Korea Other international regulatory organisations These approvals enable Symbiotec to cater to customers across highly regulated global pharmaceutical markets. Manufacturing Capabilities As of June 30, 2025, Symbiotec Pharmalab operated two industrial-scale API manufacturing facilities with: Chemical synthesis capacity: 584.67 metric tonnes (MT) Fermentation capacity: 300 kilolitres (KL) Its vertically integrated manufacturing infrastructure supports production across multiple scales while providing greater control over quality, cost, supply reliability and production processes. Research & Development Symbiotec follows a research-driven manufacturing model, with a strong focus on R&D, technological capabilities, regulatory compliance and sustainable manufacturing practices. The company's scientific expertise enables it to develop complex APIs and specialised ingredients, while also creating opportunities to expand into new products and intellectual property-driven offerings. Its products cater to the pharmaceutical, nutraceutical and wellness industries, with an emphasis on maintaining quality standards required by customers across global markets. Key Competitive Strengths Leadership in Steroidal APIs: Strong position in corticosteroid and steroidal hormone APIs, backed by specialised manufacturing expertise. Established Customer Relationships: Long-standing relationships with domestic and international pharmaceutical customers. Vertically Integrated Manufacturing: A multi-scale and backward-integrated manufacturing platform that supports operational efficiency and supply-chain control. Strong Regulatory Track Record: Manufacturing capabilities aligned with stringent global regulatory requirements, including US FDA and EU-GMP standards. Research-Driven Business Model: Continuous investment in R&D and technology, supporting the development of complex and differentiated products. Scientific & Technical Expertise: Ability to leverage existing scientific capabilities to expand its total addressable market (TAM) and enter new product categories. IP-Led Growth Opportunities: Focus on developing intellectual property-driven offerings, which could support higher-value products and future growth. Sustainable Manufacturing: Emphasis on environmentally responsible and sustainable production processes alongside quality and regulatory compliance.

Company Financials (Restated)

Period Ended 31 Mar 2026 31 Mar 2025 31 Mar 2024
Assets 1,780.79 1,579.65 1,294.79
Total Income 872.26 755.98 723.33
Profit After Tax 109.90 96.79 100.06
EBITDA 231.97 206.11 177.04
Net Worth 1,158.64 821.15 720.68
Amount in ₹ Crore

IPO Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:

# Issue Objects Est Amt (₹ Cr.)
1 Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company 112.50
2 General corporate purposes 0.00

Key Performance Indicator (KPI)

KPI Mar 31, 2026 Mar 31, 2025
ROE 11.19%% 12.66%%
ROCE 11.56%% 11.80%%
Debt/Equity - -
RoNW 9.48%% 11.79%%
PAT Margin 12.60%% 12.80%%
EBITDA Margin 26.59%% 27.26%%

Key Performance Indicator (KPI)

Pre IPO Post IPO
EPS Rs 17.82 17.39
The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2026 available in RHP. The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of March 31, 2026 available in RHP.

IPO Registrar

  • MUFG Intime India Pvt.Ltd.
  • 022-49186000
  • symbiotecpharmalab.ipo@in.mpms.mufg.com
  • Visit Website

Contact Details

Symbiotec Pharmalab Ltd. Address
385/2, Pigdamber, Rau, Mhow, Indore, Madhya Pradesh, 453331

IPO FAQs

  • What is the Aureate Tradde IPO?

    Aureate Tradde IPO is a SME IPO of 38,98,000 equity shares of the face value of ₹10 aggregating up to ₹[.] Crores. The issue is priced at To be declared. The minimum order quantity is . The Aureate Tradde IPO open and close dates are not available as of now. MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE SME.

  • How to apply in Aureate Tradde IPO through Zerodha?

    Zerodha customers can apply online in Aureate Tradde IPO using UPI as a payment gateway. Zerodha customers can apply in Aureate Tradde IPO by login into Zerodha Console (back office) and submitting an IPO application form.

    Steps to apply in Aureate Tradde IPO through Zerodha

    1. Visit the Zerodha website and login to Console.
    2. Go to Portfolio and click the IPOs link.
    3. Go to the ' Aureate Tradde IPO ' row and click the 'Bid' button.
    4. Enter your UPI ID, Quantity, and Price.
    5. Submit IPO application form.
    6. Visit the UPI App (net banking or BHIM) to approve the mandate.

    Visit Zerodha IPO Application Process Review for more detail.

  • When Aureate Tradde IPO will open?

    The Aureate Tradde IPO dates are not announced. Please check back again after some time.

  • What is the lot size of Aureate Tradde IPO?

    Aureate Tradde IPO lot size and the minimum order quantity is not available at this time. Please check again later.

  • How to apply for Aureate Tradde IPO?

    You can apply in Aureate Tradde IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.

  • Is online banking secure?

    Repudiated and annoyances accepted the wise man therefore always holds in these matters to this principle selection he rejects pleasures to secures.

  • When is Aureate Tradde IPO allotment?

    The finalization of Basis of Allotment for Aureate Tradde IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Aureate Tradde IPO allotment status.

  • When is Aureate Tradde IPO listing date ?

    The Aureate Tradde IPO listing date is not yet announced. The tentative date of listing is .